Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 463 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Severe Pain Clear all
Completed Phase 3 Interventional Results available

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780268
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
42
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 1Phase 2 Interventional

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

NCT04494386
View directory record Official record
Conditions
Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions
Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control)
Biological · Other
Lead sponsor
Restem, LLC.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Miami, Florida • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 14, 2026, 1:23 PM EDT
Completed No phase listed Observational

Quality of Life in Younger Leukemia and Lymphoma Survivors

NCT00956475
View directory record Official record
Conditions
Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Lymphoma, Lymphoproliferative Disorder, Pain, Psychosocial Effects of Cancer and Its Treatment, Small Intestine Cancer
Interventions
telephone-based intervention, questionnaire administration, assessment of therapy complications, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 14, 2026, 1:23 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

SARS Coronavirus Vaccine (SARS-CoV)

NCT00533741
View directory record Official record
Conditions
Coronavirus (SARS-CoV)
Interventions
Aluminum hydroxide, Placebo, SARS-CoV
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 2 Interventional

Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout

NCT02330796
View directory record Official record
Conditions
Gout
Interventions
Bucillamine, Colchicine
Drug
Lead sponsor
Revive Therapeutics, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
San Roman, California • Arlington, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 14, 2026, 1:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Vaccine Response in Chronic Respiratory Conditions

NCT05313087
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
COVID-19 vaccine
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 14, 2026, 1:23 PM EDT
Terminated Phase 3 Interventional Results available

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

NCT04341727
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Hydroxychloroquine Sulfate, Azithromycin, Chloroquine Sulfate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 14, 2026, 1:23 PM EDT
Withdrawn Phase 2 Interventional

Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations

NCT03277170
View directory record Official record
Conditions
Asthma; Status, Asthma in Children, Asthma Acute, Asthma Attack, Acute Asthma Exacerbation
Interventions
Montelukast Oral Granules
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

NCT05181683
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
Casirivimab+Imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 14, 2026, 1:23 PM EDT
Terminated Phase 2 Interventional Results available

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

NCT04472494
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

NCT04402970
View directory record Official record
Conditions
SARS-CoV 2, ARDS
Interventions
Dornase Alfa Inhalation Solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 14, 2026, 1:23 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

NCT04863014
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
evinacumab, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
32
States / cities
Newport Beach, California • New Haven, Connecticut • Boca Raton, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

NCT04842747
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
VERU-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • Chula Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 14, 2026, 1:23 PM EDT
Recruiting Phase 2 Interventional

Corticosteroids to Treat Pancreatitis

NCT05160506
View directory record Official record
Conditions
Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 14, 2026, 1:23 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 14, 2026, 1:23 PM EDT
Recruiting Phase 4 Interventional

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

NCT05867329
View directory record Official record
Conditions
Ulcerative Colitis Acute
Interventions
Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet, Intravenous Methylprednisolone, Prednisone Oral Product
Drug
Lead sponsor
Berinstein, Jeffrey
Other
Eligibility
18 Years to 75 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 14, 2026, 1:23 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Bioaerosol Sampling Device (BSD) Clinical Study

NCT06047067
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Cantor BioConnect, Inc.
Network
Eligibility
5 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
South Gate, California • Hollywood, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 14, 2026, 1:23 PM EDT
Completed No phase listed Observational

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.

NCT07090486
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir-ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
14,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 14, 2026, 1:23 PM EDT
Recruiting Phase 2 Interventional

Study of Novel Therapeutics for Acute Remedy of Colitis

NCT06420492
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Interventions
BRS201
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 14, 2026, 1:23 PM EDT
Terminated Phase 4 Interventional

Acute Control of Chronic Hypertension

NCT03877692
View directory record Official record
Conditions
Preeclampsia With Severe Features, Chronic Hypertension in Obstetric Context
Interventions
Experimental dosing of labetalol, Standard dosing of labetalol
Drug · Other
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 14, 2026, 1:23 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

NCT05737121
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
VNX001, Placebo, Lidocaine, Heparin
Drug
Lead sponsor
Vaneltix Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Escondido, California • Los Angeles, California • Newport Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

NCT02447848
View directory record Official record
Conditions
Moderate-to-severe Acute Pain
Interventions
sufentanil sublingual 30 mcg tablet
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Minneapolis, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 14, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits

NCT04758299
View directory record Official record
Conditions
COVID-19 Testing, Decision Making
Interventions
decision science-based design
Other
Lead sponsor
Barry Dewitt
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 14, 2026, 1:23 PM EDT
Suspended Phase 1 Interventional

Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

NCT05387278
View directory record Official record
Conditions
COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Interventions
EV-Pure™ and WJ-Pure™, Placebo
Drug
Lead sponsor
Vitti Labs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Liberty, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 1:23 PM EDT